3190 results for «358»
3190 results
It is a calcified left main: do it well, do it safely
28 Feb 2026 – From Euro4C Annual Meeting 2026
This session addresses the complexities of percutaneous coronary intervention (PCI) in calcified left main coronary artery disease. It covers comprehensive planning including mechanical circulatory support, intravascular imaging, and bifurcation strategies. Attendees will also learn to anticipate and manage potential complications and apply various tools to ensure...
ResilCard - A resilience assessment tool to ensure cardiovascular care continuity during crises
28 Feb 2026 – From Euro4C Annual Meeting 2026
Introducing ResilCard, a novel resilience assessment tool designed to maintain continuity of cardiovascular care during crises. This session highlights the importance of preparedness and adaptive strategies to ensure uninterrupted patient management in challenging healthcare environments.
The best cases of the Euro4C PCRonline website
28 Feb 2026 – From Euro4C Annual Meeting 2026
This session presents some of the most instructive and challenging cases featured on the Euro4C PCRonline website. The cases encompass management of stalled rotational atherectomy burrs, combined use of intravascular lithotripsy and Impella in saphenous vein grafts, complexities of calcium in tortuous anatomy, and strategies for...
Closing Ceremony
28 Feb 2026 – From Euro4C Annual Meeting 2026
The closing ceremony marks the conclusion of the conference, providing a summary of key learnings, acknowledgments, and final reflections on the advancements and discussions presented throughout the event.
Imaging-guided intravascular lithotripsy for calcified lesions - LIVE case
27 Feb 2026 – From Euro4C Annual Meeting 2026
This live educational case from St. Francis Hospital and Heart Center demonstrates imaging-guided intravascular lithotripsy for calcified lesions. It covers lesion selection criteria, preparation and delivery of lithotripsy catheters, and reviews recent clinical evidence to guide best practices.
LIVE Educational Case from St. Francis Hospital & Heart...
SURTAVI: five-year results from a randomized trial of TAVR vs. SAVR in patients at intermediate surgical risk
07 Nov 2021
Although TAVI is an accepted alternative to surgery in patients with severe aortic stenosis who are at high surgical risk, less is known about long-term comparative outcomes among patients with aortic stenosis who are at intermediate surgical risk. P. Redaelli & M. Pighi review the SURTAVI trial...

Author

Author
World Heart Day 2023: Reducing the burden of cardiovascular disease globally: beyond stents and balloons!
29 Sep 2023
Global burden of Cardiovascular Disease
Cardiovascular disease (CVD) remains the lead cause of mortality for men and women globally. Our world population in 2023 is 8 billion! Of these, around 620 million people are living with heart and circulatory diseases across the world. Each year around 60...

Author
The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030
29 Aug 2021
Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Author
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...

Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author